Author:
Pereira Gonçalves Julia,Fwu Shing Teng,Augusto Fonseca Alves Guilherme,Eduardo Fonseca-Alves Carlos
Abstract
Malignant melanoma is one of the most important tumors in dogs and is highly metastatic and aggressive disease. In recent years, molecular knowledge regarding canine melanoma has increased, and some chromosomal imbalances and tyrosine kinase pathways have been identified to be dysregulated. Mxoreover, canine melanoma is an immunogenic tumor that provides opportunities to administer immunotherapy to the patient. Podoplanin and chondroitin sulfate proteoglycan-4 (CSPG4) are markers against which monoclonal antibodies have been developed and tested in dogs in vivo with promising results. Owing to the importance of canine melanoma in the veterinary oncology field, this chapter reviews the most important aspects related to immunological involvement in the prognosis and treatment of canine melanoma.
Reference53 articles.
1. Fonseca-Alves CE, Ferreira Ê, de Oliveira MC, Strauss BE, Fávaro WJ, Durán N, et al. Current Status of Canine Melanoma Diagnosis and Therapy: Report From a Colloquium on Canine Melanoma Organized by ABROVET (Brazilian Association of Veterinary Oncology). Frontiers in Veterinary Science. 2021;8:707025
2. Bergman PJ. Canine oral melanoma. Clinical Techniques in Small Animal Practice. May 2007;22(2):55-60. DOI: 10.1053/j.ctsap.2007.03.004. PMID: 17591290
3. Manzan M, Junior RRS, Perinelli A, et al. Considerations about Malignant Melanoma in Dogs: A Histological Approach. Brasília: Veterinary Medicine Bulletin; 2005
4. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Veterinary Pathology. 2002;39(6):651-678
5. Nishiya AT, Massoco CO, Felizzola CR, Perlmann E, Batschinski K, Tedardi MV, et al. Comparative aspects of canine melanoma. Veterinary Science. 2016;3:7